Catapult Therapeutics is a clinical-stage biopharmaceutical company specializing in targeted therapy for cancer. Their flagship product, CAP-100, is an anti-CCR7 antibody with a unique mechanism of action that interferes with the fundamental pathology of hematological malignancies. CAP-100 has demonstrated the ability to treat primary tumor cells from patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHL), by interrupting tumor cell migration and promoting cell killing while preserving normal blood cells.

Catapult Therapeutics was founded in 2015 as a joint venture between Spanish and Dutch partners, built upon the discoveries of Dr. Cecilia Munoz and her group at Hospital La Princesa in Madrid. The company's phase I clinical trial for CAP-100 is currently underway at the Dana-Farber Cancer Institute in Boston and other leading clinical sites in the USA, with plans for expansion to Europe in fall 2022.

The team at Catapult Therapeutics is led by experienced managers and scientists from the Netherlands and Spain, including CEO Dominik Höchli and Scientific Advisor Wiebe Olijve. Their expertise and dedication drive the development and advancement of innovative targeted therapies for cancer treatment